IMS Health
Innovation in oncology continues to dominate the drug development pipeline, with accelerated approvals, increased funding and awareness, and an overall pipeline of almost 2,000 active products under study accounting for one-third of all pharmaceutical R&D. However, while many oncology indications are experiencing success in life extension with overall five-year survival rates at more than 66%, others such as lung cancer are struggling to achieve the same results, with a mere 16.8% of patients achieving five-year survival. While these rates may be low, innovation in lung cancer is at an all-time high; extending survival of lung cancer patients has become a large industry investment.
However, an interesting finding is that the U.S. has remained cost neutral over the last five years in R&D cost per-patient spend, in addition to remaining visit neutral in the area of lung cancer research (see chart). Ex-U.S. has experienced the opposite—with a correlation between increased patient visits and increased per-patient spend. What is fueling this increase in activity? Is this purely a result of globalization of research over the past five years? Or perhaps the U.S. has become more efficient in execution, thus controlling spend, but with little new outcomes. — IMS Health
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.